glp-1 microdosing research is popular, but there's little evidence it works THE PCCA BLOG | Microdosing

The GLP-1R/GIPR/GcgR triple-agonist retatrutide achieves body weight loss (~25%) in just two-thirds of the time, potentially surpassing the efficacy of Roux-en-Y gastric bypass [29]

Other patients take GLP-1s for a period of time, go off of them for a while, and then resume the medication later as needed

Heerspink HJL, Stefansson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al

Some explanations for these strong effects come from mechanistic studies investigating the proportions of the respective GLP-1 and GIP receptor agonistic properties

Overexpression of glutamine:fructose-6-phosphate-amidotransferase induces transforming growth factor-beta1 synthesis in NIH-3T3 fibroblasts

the key difference is MedVi's always-on availability